Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Melero

Showing results (121-130 of 351) with videos related to

Pageof 36
Sort By:
Oncoimmunology|December 18, 2012
Virotherapy, gene transfer and immunostimulatory monoclonal antibodiesJosé I Quetglas, Liza B John, Michael H Kershaw, et al.
Drugs|May 28, 2016
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?Lucia Festino, Gerardo Botti, Paul Lorigan, et al.
Cancer Immunology, Immunotherapy : CII|September 6, 2018
International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, SpainPedro Berraondo, Maria Angela Aznar, Elisabeth Perez-Ruiz, et al.
International Journal of Cancer|April 1, 2004
Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigensIñigo Tirapu, Ainhoa Arina, Guillermo Mazzolini, et al.
Journal for Immunotherapy of Cancer|April 26, 2014
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAbAizea Morales-Kastresana, Elena Catalán, Sandra Hervás-Stubbs, et al.
Seminars in Oncology|August 31, 2015
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOSMiguel F Sanmamed, Fernando Pastor, Alfonso Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell deathIgnacio Melero, Izaskun Gabari, Iñigo Tirapu, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 17, 2010
Selection of extreme phenotypes: the role of clinical observation in translational researchJosé Luis Pérez-Gracia, Alfonso Gúrpide, María Gloria Ruiz-Ilundain, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Awareness and understanding of cancer immunotherapy in EuropeHåkan Mellstedt, Gustav Gaudernack, Winald R Gerritsen, et al.
Immunological Reviews|October 12, 2023
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-primingCarlos Luri-Rey, Gabriel Gomis, Javier Glez-Vaz, et al.
Pageof 36

Showing results (121-130 of 351) with videos related to

Sort By:
Pageof 36
Oncoimmunology|December 18, 2012
Virotherapy, gene transfer and immunostimulatory monoclonal antibodiesJosé I Quetglas, Liza B John, Michael H Kershaw, et al.
Drugs|May 28, 2016
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?Lucia Festino, Gerardo Botti, Paul Lorigan, et al.
Cancer Immunology, Immunotherapy : CII|September 6, 2018
International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, SpainPedro Berraondo, Maria Angela Aznar, Elisabeth Perez-Ruiz, et al.
International Journal of Cancer|April 1, 2004
Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigensIñigo Tirapu, Ainhoa Arina, Guillermo Mazzolini, et al.
Journal for Immunotherapy of Cancer|April 26, 2014
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAbAizea Morales-Kastresana, Elena Catalán, Sandra Hervás-Stubbs, et al.
Seminars in Oncology|August 31, 2015
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOSMiguel F Sanmamed, Fernando Pastor, Alfonso Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell deathIgnacio Melero, Izaskun Gabari, Iñigo Tirapu, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 17, 2010
Selection of extreme phenotypes: the role of clinical observation in translational researchJosé Luis Pérez-Gracia, Alfonso Gúrpide, María Gloria Ruiz-Ilundain, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Awareness and understanding of cancer immunotherapy in EuropeHåkan Mellstedt, Gustav Gaudernack, Winald R Gerritsen, et al.
Immunological Reviews|October 12, 2023
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-primingCarlos Luri-Rey, Gabriel Gomis, Javier Glez-Vaz, et al.
Pageof 36